Dr. Reddy's Plans to Launch Generic Ozempic in Canada This Month, Targets Semaglutide Tablet Launch in India
📊 GOOGL — Piyasa Yorumu
■ neutral · 30%The news headline is not directly related to GOOGL, focusing instead on Dr Reddy's generic drug launch. Technical indicators present a weak short-term outlook: RSI at 42 in neutral territory, MACD below the signal line, and price below the 20- and 50-day moving averages. A 2.3% decline in the last 24 hours confirms selling pressure. However, due to the lack of direct news impact, directional uncertainty is high. The short-term downtrend may persist, but no strong signal is evident.
📊 RDY — Piyasa Yorumu
▲ up · 60%The news creates a positive catalyst for Dr Reddy's. The launch of generic Ozempic in Canada and the release of semaglutide tablets in India could enhance the company's growth potential. However, the stock has fallen 7.87% in the last 24 hours, with an RSI of 25.9 indicating oversold conditions. These technical indicators support the possibility of a short-term recovery. Although the MACD is in negative territory, the positive momentum generated by the news may limit further declines. A short-term upward movement is possible, but caution is advised as the downtrend has not been fully broken.